Defibrotide如何使用？

Defibrotide (Defibrotide) is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). On October 22, 2013, Defibrotide was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. Defibrotide is a DNA-derived anticoagulant used to treat hepatic veno-occlusive disease and renal or pulmonary insufficiency following hematopoietic stem cell transplantation. Defibrotide has received marketing authorization from the European Commission for the treatment of severe hepatic VOD in hematopoietic stem cell transplantation (HSCT). A phase 3 randomized controlled trial of defibrination to prevent hepatic VOD in pediatric transplant patients has also been completed. Defibrotide has been generally well tolerated; the most common adverse reactions observed during premarketing use of defibrotide for the treatment of hepatic VOD were bleeding, hypotension, and coagulopathy.

VOD is a potentially life-threatening condition that often occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of a stem cell transplant may damage the cells lining the liver blood vessels and cause VOD, leading to liver failure and possibly significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). Hematopoietic stem cell transplantation is a frequently used treatment modality for blood cancers and other conditions in adults and children.

How to use Defibrotide: 1. Give Defibrotide (Defibrotide) 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion. 2. The total duration of treatment is a minimum of 21 days. If the signs and symptoms of VOD do not resolve after 21 days. Continue treatment until resolution.